FDA Approves Capivasertib with Abiraterone and Prednisone for PTEN-deficient Androgen Pathway Modulation-Naïve or -Sensitive Prostate Cancer By Ogkologos - July 15, 2026 208 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR £82,000 of Donations Pour in for Mom with Incurable Cancer to... April 10, 2019 Approximately 1 Million of New Maternal Orphans Due to Cancer in... November 28, 2022 Mom’s Topless Photo Is Supposed To Encourage Breastfeeding, But Some Think... March 19, 2019 Scientists Find Genetic Changes Linked to Cancer in Children March 4, 2025 Load more HOT NEWS Doctors Said Egg-Sized Tumor Was Benign. A Year Later, She’s Fighting... Nivolumab Plus AVD Prolongs PFS in Adolescents and Adults with Advanced-Stage... FDA Approves Pembrolizumab Combination for the First-Line Treatment of Cervical Cancer Professional Runner and Mom of Two Shares Photo Of Belly Cavity...
